Roth Capital Maintains Buy on PolyPid, Lowers Price Target to $9

Benzinga · 06/18 16:32
Roth Capital analyst Boobalan Pachaiyappan maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers the price target from $12 to $9.